(VIR) Vir Biotechnology - Ratings and Ratios
HDV, RSV, HPV, Coronavirus, TCE
VIR EPS (Earnings per Share)
VIR Revenue
Description: VIR Vir Biotechnology October 21, 2025
Vir Biotechnology (NASDAQ:VIR) is a clinical-stage biopharma focused on developing therapeutic products for serious infectious diseases and, more recently, solid-tumor oncology. Founded in 2016 and based in San Francisco, the company operates primarily in the United States but maintains a global development footprint.
The current pipeline includes two late-stage investigational therapies: one targeting hepatitis delta virus (HDV) and another aimed at solid-tumor indications. Preclinical programs span influenza A/B, COVID-19, respiratory syncytial virus (RSV), human metapneumovirus (MPV), and human papillomavirus (HPV), reflecting a broad infectious-disease platform.
Vir leverages a network of strategic alliances: a grant from the Gates Foundation, an option/licensing deal with Brii Biosciences, a collaboration with Alnylam on RNA-targeted therapeutics, licensing arrangements with MedImmune (a subsidiary of AstraZeneca), a research partnership with GlaxoSmithKline, and a licensing agreement with Sanofi covering three masked T-cell engagers (TCEs) and exclusive use of its protease-cleavable masking technology for oncology and infectious-disease applications.
Key quantitative signals (as of the most recent 10-Q) show a cash runway of roughly $300 million, R&D spend of $150 million in the trailing twelve months, and a market capitalization near $2.1 billion. The infectious-disease sector is being buoyed by heightened post-pandemic funding, a 12-month average biotech funding growth rate of ~8 %, and accelerating adoption of platform-based antibody engineering-factors that could amplify Vir’s valuation if its late-stage candidates achieve regulatory clearance.
For a deeper, data-driven assessment of Vir’s valuation dynamics, you may find the analyst tools on ValueRay useful for exploring scenario-based price targets and comparable peer metrics.
VIR Stock Overview
| Market Cap in USD | 828m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-10-11 |
VIR Stock Ratings
| Growth Rating | -84.5% |
| Fundamental | 33.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -52.9% |
| Analyst Rating | 4.0 of 5 |
VIR Dividends
Currently no dividends paidVIR Growth Ratios
| Growth Correlation 3m | 87.7% |
| Growth Correlation 12m | -72% |
| Growth Correlation 5y | -93.4% |
| CAGR 5y | -41.04% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.48 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.69 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -66.13 |
| Beta | 1.273 |
| Volatility | 71.73% |
| Current Volume | 1106k |
| Average Volume 20d | 1293k |
| Stop Loss | 5 (-7.4%) |
| Signal | -0.72 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-550.2m TTM) > 0 and > 6% of Revenue (6% = 1000.0k TTM) |
| FCFTA -0.39 (>2.0%) and ΔFCFTA -11.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3784 % (prev 1406 %; Δ 2378 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.38 (>3.0%) and CFO -457.4m > Net Income -550.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (138.4m) change vs 12m ago 1.62% (target <= -2.0% for YES) |
| Gross Margin 95.53% (prev 81.99%; Δ 13.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.16% (prev 4.72%; Δ -3.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.35 (EBITDA TTM -584.9m / Interest Expense TTM 74.9m) >= 6 (WARN >= 3) |
Altman Z'' -5.73
| (A) 0.53 = (Total Current Assets 735.7m - Total Current Liabilities 105.0m) / Total Assets 1.19b |
| (B) -0.83 = Retained Earnings (Balance) -991.7m / Total Assets 1.19b |
| (C) -0.33 = EBIT TTM -475.1m / Avg Total Assets 1.43b |
| (D) -4.06 = Book Value of Equity -993.9m / Total Liabilities 245.1m |
| Total Rating: -5.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.95
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.10 = 2.50 |
| 5. Debt/Ebitda 0.35 = 2.41 |
| 6. ROIC - WACC (= -52.95)% = -12.50 |
| 7. RoE -50.22% = -2.50 |
| 8. Rev. Trend -70.05% = -5.25 |
| 9. EPS Trend 46.00% = 2.30 |
What is the price of VIR shares?
Over the past week, the price has changed by -8.63%, over one month by -3.40%, over three months by +5.68% and over the past year by -43.98%.
Is Vir Biotechnology a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VIR is around 3.27 USD . This means that VIR is currently overvalued and has a potential downside of -39.44%.
Is VIR a buy, sell or hold?
- Strong Buy: 2
- Buy: 5
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VIR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.2 | 218.9% |
| Analysts Target Price | 17.2 | 218.9% |
| ValueRay Target Price | 3.7 | -31.9% |
VIR Fundamental Data Overview November 02, 2025
P/E Forward = 4.3611
P/S = 43.5759
P/B = 0.8299
Beta = 1.273
Revenue TTM = 16.7m USD
EBIT TTM = -475.1m USD
EBITDA TTM = -584.9m USD
Long Term Debt = 102.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.75m USD (from shortTermDebt, last fiscal year)
Debt = 93.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -205.9m USD (from netDebt column, last quarter)
Enterprise Value = 234.4m USD (827.9m + Debt 93.4m - CCE 687.0m)
Interest Coverage Ratio = -6.35 (Ebit TTM -475.1m / Interest Expense TTM 74.9m)
FCF Yield = -199.0% (FCF TTM -466.4m / Enterprise Value 234.4m)
FCF Margin = -2798 % (FCF TTM -466.4m / Revenue TTM 16.7m)
Net Margin = -3302 % (Net Income TTM -550.2m / Revenue TTM 16.7m)
Gross Margin = 95.53% ((Revenue TTM 16.7m - Cost of Revenue TTM 745.0k) / Revenue TTM)
Gross Margin QoQ = 99.09% (prev 100.0%)
Tobins Q-Ratio = 0.20 (Enterprise Value 234.4m / Total Assets 1.19b)
Interest Expense / Debt = 0.26% (Interest Expense 239.0k / Debt 93.4m)
Taxrate = 0.15% (-170.0k / -110.8m)
NOPAT = -474.4m (EBIT -475.1m * (1 - 0.15%)) [loss with tax shield]
Current Ratio = 7.01 (Total Current Assets 735.7m / Total Current Liabilities 105.0m)
Debt / Equity = 0.10 (Debt 93.4m / totalStockholderEquity, last quarter 947.5m)
Debt / EBITDA = 0.35 (negative EBITDA) (Net Debt -205.9m / EBITDA -584.9m)
Debt / FCF = 0.44 (negative FCF - burning cash) (Net Debt -205.9m / FCF TTM -466.4m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -46.14% (Net Income -550.2m / Total Assets 1.19b)
RoE = -50.22% (Net Income TTM -550.2m / Total Stockholder Equity 1.10b)
RoCE = -39.66% (EBIT -475.1m / Capital Employed (Equity 1.10b + L.T.Debt 102.2m))
RoIC = -43.30% (negative operating profit) (NOPAT -474.4m / Invested Capital 1.10b)
WACC = 9.65% (E(827.9m)/V(921.3m) * Re(10.71%) + D(93.4m)/V(921.3m) * Rd(0.26%) * (1-Tc(0.00)))
Discount Rate = 10.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.37%
Fair Price DCF = unknown (Cash Flow -466.4m)
EPS Correlation: 46.00 | EPS CAGR: 25.24% | SUE: 2.78 | # QB: 1
Revenue Correlation: -70.05 | Revenue CAGR: -87.52% | SUE: -0.06 | # QB: 0
Additional Sources for VIR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle